Download PDF
Thromb Haemost
DOI: 10.1055/a-2615-4513
Stroke, Systemic or Venous Thromboembolism

Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence

Pedro Ruiz-Artacho 
1   Department of Internal Medicine, Clínica Universidad de Navarra, Madrid, Spain
2   Interdisciplinar Teragnosis and Radiosomics Research Group (INTRA-Madrid), Universidad de Navarra, Madrid, Spain
3   CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
,
Ramón Lecumberri 
4   Department of Haematology, Clínica Universidad de Navarra, Pamplona, Spain
5   CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
,
Javier Trujillo-Santos
6   Department of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
7   Universidad Católica San Antonio de Murcia, Murcia, Spain
,
Fahd Beddar Chaib
8   Emergency Department, Complejo Asistencial de Soria, Soria, Spain
9   Faculty of Health Sciences, Universidad de Valladolid, Valladolid, Spain
,
Farès Moustafa
10   Emergency Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
,
Alicia Lorenzo
11   Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain
,
Covadonga Gómez-Cuervo 
12   Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
,
Marijan Bosevski 
13   University Stt. Cyril and Methodius, Faculty of Medicine, University Clinic of Cardiology, Skopje, North Macedonia
,
Manuel Monreal
3   CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
14   Chair for the Study of Thromboembolic Disease, Faculty of Health Sciences, UCAM—Universidad Católica San Antonio de Murcia, Spain
,
the RIETE Investigators› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints


Abstract

Background

Evidence on the use of direct oral anticoagulants (DOACs) in upper extremity deep vein thrombosis (UEDVT) remains limited. This study examines real-world outcomes of DOACs compared with standard anticoagulation therapy for UEDVT patients.

Methods

Using the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) database, we conducted an observational analysis of UEDVT patients treated with DOACs or standard therapy (low molecular weight heparin [LMWH] or vitamin K antagonists for noncancer patients, and LMWH for cancer patients). Patients with events during the first 5 days of treatment were excluded. The primary outcome was a composite of venous thromboembolism (VTE) recurrence and major bleeding during the first 3 months of therapy. Multivariable and multilevel analyses were conducted to adjust for confounding.

Results

Between January 2011 and November 2023, 3,496 UEDVT patients met the inclusion criteria. Of these, 679 (19.4%) received DOACs, whereas 2,817 (80.6%) received standard therapy. The composite outcome occurred in seven patients (1.0%) on DOACs (5 [0.7%] VTE recurrence, 2 [0.3%] major bleeding) compared with 78 patients (2.8%) on standard therapy (51 [1.8%] VTE recurrence, 29 [1.0%] major bleeding; p < 0.001). Multivariable analysis showed that DOAC use was associated with a lower risk of the composite outcome (adjusted subhazard ratio: 0.41; 95% confidence interval: 0.19–0.90). These findings remained consistent in multilevel models and sensitivity analyses stratified by cancer and catheter-related thrombosis.

Conclusion

This real-world analysis suggests that DOACs may be associated with a lower risk of VTE recurrence and major bleeding compared with standard therapy in patients with UEDVT. These findings support DOACs as a viable treatment option.

Keywords

upper extremity deep vein thrombosis - direct oral anticoagulants - catheter-related thrombosis

Authors' Contribution

P.R.A., R.L., J.T.S., and M.M. designed the study, analyzed the data, and drafted the manuscript. F.B.C., F.M., A.L., C.G.C, and M.B. critically reviewed and edited the manuscript. All the authors approved the final version of the manuscript.


* A full list of RIETE investigators is provided in the [Supplementary Appendix] (available in the online version).


Supplementary Material



Publication History

Received: 16 February 2025

Accepted: 18 May 2025

Accepted Manuscript online:
19 May 2025

Article published online:
29 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Muñoz FJ, Mismetti P, Poggio R. et al; RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133 (01) 143-148
    CrossrefPubMedSearch in Google Scholar
  • 2 Porfidia A, Porceddu E, Feliciani D. et al. Differences in clinical presentation, rate of pulmonary embolism, and risk factors among patients with deep vein thrombosis in unusual sites. Clin Appl Thromb Hemost 2019; 25: 1076029619872550
    CrossrefPubMedSearch in Google Scholar
  • 3 Ageno W, Haas S, Weitz JI. et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (02) 319-327
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Delluc A, Le Mao R, Tromeur C. et al. Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. Haematologica 2019; 104 (01) e29-e31
    CrossrefPubMedSearch in Google Scholar
  • 5 Bosch FTM, Nisio MD, Büller HR, van Es N. Diagnostic and therapeutic management of upper extremity deep vein thrombosis. J Clin Med 2020; 9 (07) 2069
    CrossrefPubMedSearch in Google Scholar
  • 6 Potere N, Candeloro M, Porreca E, DI Nisio M. Management of upper extremity deep vein thrombosis: an updated review of the literature. Minerva Med 2021; 112 (06) 746-754
    PubMedSearch in Google Scholar
  • 7 Kakkos SK, Gohel M, Baekgaard N. et al; Esvs Guidelines Committee. Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg 2021; 61 (01) 9-82
    CrossrefPubMedSearch in Google Scholar
  • 8 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: [email protected]. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (05) 452-467
    CrossrefPubMedSearch in Google Scholar
  • 9 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedSearch in Google Scholar
  • 10 Newton DH, Monreal Bosch M, Amendola M. et al; RIETE Investigators. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. J Vasc Surg Venous Lymphat Disord 2017; 5 (01) 18-24.e1
    PubMedSearch in Google Scholar
  • 11 Houghton DE, Casanegra AI, Peterson LG. et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol 2020; 95 (07) 817-823
    PubMedSearch in Google Scholar
  • 12 Montiel FS, Ghazvinian R, Gottsäter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J 2017; 15: 26
    CrossrefPubMedSearch in Google Scholar
  • 13 Ligia S, Musiu P, Serrao A. et al. Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis. J Thromb Thrombolysis 2023; 56 (02) 323-326
    CrossrefPubMedSearch in Google Scholar
  • 14 Vedovati MC, Tratar G, Mavri A. et al. Upper extremities deep vein thrombosis treated with oral direct anticoagulants: a prospective cohort study. Int J Cardiol 2021; 339: 158-163
    CrossrefPubMedSearch in Google Scholar
  • 15 Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol 2017; 92 (01) E9-E10
    PubMedSearch in Google Scholar
  • 16 Davies GA, Lazo-Langner A, Gandara E. et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res 2018; 162: 88-92
    CrossrefPubMedSearch in Google Scholar
  • 17 Fan F, Zou Y, Zhang S. et al. Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis. Clin Ther 2017; 39 (09) 1882-1888
    PubMedSearch in Google Scholar
  • 18 Porfidia A, Agostini F, Giarretta I. et al. Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis 2020; 50 (02) 355-360
    CrossrefPubMedSearch in Google Scholar
  • 19 Schastlivtsev I, Lobastov K, Tsaplin S. et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: a single-center experience and review of the literature. Thromb Res 2019; 181: 24-28
    PubMedSearch in Google Scholar
  • 20 Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C. et al. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clin Transl Oncol 2017; 19 (08) 997-1009
    PubMedSearch in Google Scholar
  • 21 Kovacs MJ, Kahn SR, Rodger M. et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5 (08) 1650-1653
    CrossrefPubMedSearch in Google Scholar
  • 22 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 (Suppl. 01) S72-S81
    CrossrefPubMedSearch in Google Scholar
  • 23 Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc 2015; 4 (08) e002322
    CrossrefPubMedSearch in Google Scholar
  • 24 Chan NC, Weitz JI, Eikelboom JW. Anticoagulation for mechanical heart valves: will oral factor Xa inhibitors be effective?. Arterioscler Thromb Vasc Biol 2017; 37 (05) 743-745
    CrossrefPubMedSearch in Google Scholar
  • 25 Guan Z, Wang R, Hussain RH, Fredenburgh JC, Jaffer IH, Weitz JI. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. J Thromb Haemost 2023; 21 (01) 76-82
    PubMedSearch in Google Scholar
  • 26 Bikdeli B, Jimenez D, Hawkins M. et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Jiménez D, Bikdeli B, Quezada A. et al; RIETE investigators. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ 2019; 366: l4416
    CrossrefPubMedSearch in Google Scholar
  • 28 Avnery O, Martin M, Bura-Riviere A. et al; RIETE Investigators. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med 2020; 287 (01) 32-41
    PubMedSearch in Google Scholar
  • 29 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSearch in Google Scholar
  • 30 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedSearch in Google Scholar
  • 31 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Thieme ConnectPubMedSearch in Google Scholar
  • 32 Valeriani E, Di Nisio M, Porceddu E. et al. Anticoagulant treatment for upper extremity deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2022; 20 (03) 661-670
    CrossrefPubMedSearch in Google Scholar